ArticleCurrent opinion in systems biology2021
Design and development of engineered receptors for cell and tissue engineering.
Article in Current opinion in systems biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Targeted Lysosomal Degradation of Extracellular and Membrane Proteins: From Receptor Hijacking to Programmable Endolysosomal Routing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems.Advanced drug delivery reviews · 2026Review
- Advancements in DNA-Driven Precision Modulation of Cell Surface Receptor for Programmable Cellular Functions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Advancing cell therapies with artificial intelligence and synthetic biology.Current opinion in biomedical engineering · 2025Article
- Programming megakaryocytes to produce engineered platelets for delivering non-native proteins.Communications biology · 2025Article
- Exploring structure-function relationships in engineered receptor performance using computational structure prediction.GEN biotechnology · 2025Article
- Engineering signalling pathways in mammalian cells.Nature biomedical engineering · 2024Review
- Using Chemistry To Recreate the Complexity of the Extracellular Matrix: Guidelines for Supramolecular Hydrogel-Cell Interactions.Journal of the American Chemical Society · 2024Review
- Advancing in vivo reprogramming with synthetic biology.Current opinion in biotechnology · 2024Review
- Designer cell therapy for tissue regeneration.Inflammation and regeneration · 2024Review
- Programmable synthetic receptors: the next-generation of cell and gene therapies.Signal transduction and targeted therapy · 2024Review
- Design and mathematical analysis of activating transcriptional amplifiers that enable modular temporal control in synthetic juxtacrine circuits.Synthetic and systems biotechnology · 2023Article
- Mechanochemical feedback loops in contact-dependent fate patterning.Current opinion in systems biology · 2023Review
- Engineering receptors in the secretory pathway for orthogonal signalling control.Nature communications · 2022Article
- Engineering multiscale structural orders for high-fidelity embryoids and organoids.Cell stem cell · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Advances in synthetic biology have provided genetic tools to reprogram cells to obtain desired cellular functions that include tools to enable the customization of cells to sense an extracellular signal and respond with a desired output. These include a variety of engineered receptors capable of transmembrane signaling that transmit information from outside of the cell to inside when specific ligands bind to them. Recent advances in synthetic receptor engineering have enabled the reprogramming of cell and tissue behavior, controlling cell fate decisions, and providing new vehicles for therapeutic delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.